Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
- Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED category NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of a subsequent analysis of its pivotal study aimed at facilitating FDA-approved OTC access of the Company's STENDRA® (avanafil) for consumers. This analysis suggested support for the primary study results and demonstrated improved correct self-selection outcomes resulting from patients using the Company's proprietary Web App Technology and its embedded clinically validated diagnostic tool relative to subsequent verbal interviews that were designed into the study protocol as a form of validation of an ED diagnosis.
- 07/29/2024
|
Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
- Vital study aligned with FDA guidelines shows encouraging performance as Petros continues close FDA contact for a potential technology-centered Rx-to-OTC switch NEW YORK, NY / ACCESSWIRE / July 16, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating FDA-approved OTC access of STENDRA® (avanafil) for consumers. The pivotal self-selection study showed that consumers who used the Company's proprietary Web App Technology, designed to assist in the appropriate consumer self-selection for receiving the drug, had a statistically significant (p
- 07/16/2024
|
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
- Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company's prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co. (Nasdaq: ME), and a leading telemedicine provider. "With Lemonaid's nationwide distribution and industry leading track record of treating a significant number of ED patients across the country, we are excited to collaborate with Lemonaid Health in this expanded access initiative for STENDRA.
- 05/14/2024
|
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
- Collaboration with leading telemedicine provider to offer marketing and distribution of STENDRA for Lemonaid Health's ED patients (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 23, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new collaboration with Lemonaid Health, leading telemedicine provider and a subsidiary of 23andMe, serving hundreds of thousands of patients with quality healthcare. As part of the collaboration, prescription STENDRA® (avanafil) in all strengths will be available through Lemonaid Health's telehealth platform.
- 04/23/2024
|
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
- (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received positive feedback from the U.S. Food and Drug Administration (the "FDA," or the "Agency") following the FDA's informal review of Petros' technology component for self-selection as the Company endeavors to achieve OTC status for STENDRA. The Agency acknowledged that the technology addressed some of its concerns regarding the PDE5 inhibitor class in that context, particularly with regard to nitrate-using patients.
- 04/16/2024
|
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
- Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an OTC setting (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces positive results of an initial cohort of its self-selection study comparing the use of a Drug Facts Label (DFL) alone to a DFL in combination with a web app (technology component).
- 04/02/2024
|
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
- Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC Status (Please see important safety information below) NEW YORK, NY / ACCESSWIRE / March 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has successfully launched its artificial intelligence (AI) tool developed as a result of its collaboration with a multi-billion-dollar software developer. The tool is being integrated into the Company's web app being used for patient self-screening, which it is testing in its recently launched Human Factors study.
- 03/19/2024
|
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
- AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counter NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as part of the Company's ongoing efforts to bring STENDRA over the counter. The technology will be integrated into the core tool the Company has already developed as part of its Self-Selection Study, which is currently underway.
- 02/14/2024
|
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
- FDA requests meeting to review the Company's technology component and discuss further development and requirements NEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has scheduled two meetings with the U.S. Food and Drug Administration (FDA) to review the Company's progress and path forward in developing STENDRA as the first PDE-5 inhibitor approved as an over-the-counter medication for erectile dysfunction. (Please see Important Safety Information below.
- 01/24/2024
|
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
- Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA® working to become the first erectile dysfunction medication to successfully achieve OTC status NEW YORK, NY / ACCESSWIRE / January 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the successful completion of the initial cohort of a Phase 2 equivalent Self-Selection Study (SSS).
- 01/17/2024
|
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
- Human Factor Study represents important component of FDA requirements for technology to pave way for STENDRA OTC approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the completion of a Human Factors Study, whose objective was to assess the technology component developed to facilitate patient's access to its erectile dysfunction drug, STENDRA® (avanafil), associated with the Company's intended FDA application for prescription to OTC switch. The objective of the study was to determine the strengths and weaknesses of the interface of a developmental technology tool, as well as potential use errors in critical tasks, such as navigating and reporting medical history, entering birth date and other key call to action prompts.
- 12/12/2023
|
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
- Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval NEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces its partnership with Idea Evolver (IE), a Technology platform for Rx-to-OTC switches and digital pharmaceutical launch solutions. The partnership will focus on developing an application to help facilitate the technology element for the Company's prescription to OTC switch for its erectile dysfunction drug STENDRA® (avanafil).
- 12/12/2023
|
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider
- Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch Approval NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces its partnership with Idea Evolver (IE), a Technology platform for Rx-to-OTC switches and digital pharmaceutical launch solutions. The partnership will focus on developing an application to help facilitate the technology element for the Company's prescription to OTC switch for its erectile dysfunction drug STENDRA® (avanafil).
- 12/05/2023
|
Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)
- New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTC Petros in discussions with third-party technology partners NEW YORK, NY / ACCESSWIRE / October 30, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), ), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the development of a technological component of its self-selection study utilizing machine learning/artificial intelligence (AI), which the Company plans to integrate into its self-selection studies for its erectile dysfunction drug STENDRAÒ (avanafil). The development of the technology and study design will continue to follow direct U.S. Food and Drug Administration (FDA) recommendations as well as published proposed guidelines currently being finalized by the Agency.
- 10/30/2023
|
Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA
- Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC Status NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs, announces initiation of a self-selection study using the Drug Facts Label (DFL) tested during its previously announced label comprehension study (LCS). Fady Boctor, Petros' President and Chief Commercial Officer, commented, "We continue to collaborate with the FDA as we pursue an emerging pathway to expand access to STENDRA as the first potential OTC prescription-grade therapeutic option for erectile dysfunction (ED).
- 10/19/2023
|
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label
- Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRA NEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) nonprescription pathways, announces completion of a pivotal label comprehension study (LCS). Using FDA guidance provided to the company in 2022, the LCS is expected to satisfy a critical step in the organization's progress towards a possible non-prescription version of STENDRA, the Company's prescription erectile dysfunction drug.
- 10/04/2023
|
Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
- NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 - 5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles.
- 09/28/2023
|
Petros Pharmaceuticals Provides Letter to Shareholders
- NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders: To our valued shareholders, As we approach the fourth quarter of 2023, Petros has been quietly undergoing a change in approach to our business. As we have previously announced, our evolving focus has shifted from prioritizing the commercialization of prescription STENDRA, which continues to be a source of revenue for us, to developing and executing on a new pathway toward non-prescription or potentially over-the-counter access for our current lead product.
- 09/11/2023
|
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.
- 09/06/2023
|
Petros Pharmaceuticals Announces Capital Raise of $15 Million
- Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRA NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the over the counter (OTC) pathway, today announces a $15 million private placement financing that will support its continued progress towards bringing its erectile dysfunction (ED) drug, STENDRA, to non-prescription OTC status. Petros raised $15 million from this private placement, which was led by its largest existing shareholders.
- 07/13/2023
|
Top Penny Stocks Chart Patterns to Use to Profit
- Use these top charts to profit with penny stocks The post Top Penny Stocks Chart Patterns to Use to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/26/2023
|
Penny Stock Due Diligence: Top Research Techniques
- Use these tips for researching penny stocks in 2023 The post Penny Stock Due Diligence: Top Research Techniques appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/17/2023
|
Buying Energy Penny Stocks? 3 Methods to Use
- Investing in energy penny stocks? Here's some top tips The post Buying Energy Penny Stocks?
- 04/16/2023
|
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
- NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022. The conference is being held on May 3 – 5, 2022 at The Bally's Hotel & Casino in Las Vegas, NV.
- 04/27/2022
|
3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week
- Can these penny stocks climb this coming week? The post 3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/24/2022
|
Best Penny Stocks, How To Buy & Strategies for Beginners
- Are these strategies on your list for buying penny stocks next month? The post Best Penny Stocks, How To Buy & Strategies for Beginners appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/24/2022
|
What Are Penny Stocks? What You Need to Know and 3 to Watch
- Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/20/2022
|
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
- NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q1 Investor Summit Conference, which is being held virtually on March 8 – 9, 2022.
- 03/03/2022
|
Best Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch
- Are short squeeze penny stocks part of your strategy this week? The post Best Penny Stocks To Buy This Week?
- 01/30/2022
|
3 Reddit Penny Stocks For Your Watch List In January 2022
- Reddit penny stocks to watch this week. The post 3 Reddit Penny Stocks For Your Watch List In January 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/10/2022
|
Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop
- These five top short squeeze stocks are among the top speculative plays investors and traders are watching in today's market. The post Short Squeeze Stocks: ISIG, RELI and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.
- 01/10/2022
|
Short Squeeze Stocks: ISIG, AVCT and 5 Others Experts Think Are Ready to Pop
- As the new year kicks off, investors are looking forward to another positive year in the markets. And interest in short squeeze stocks has not waned.
- 01/03/2022
|
4 Penny Stocks To Buy For Under $5 With High Short Interest
- Short squeeze penny stocks to watch this week. The post 4 Penny Stocks To Buy For Under $5 With High Short Interest appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/03/2022
|
Top Penny Stocks to Buy Now? Check These 3 Out For the New Year
- Check these three penny stocks out for your watchlist right now The post Top Penny Stocks to Buy Now? Check These 3 Out For the New Year appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/27/2021
|
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard
- Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
- 12/27/2021
|
What Are Penny Stocks, How to Trade Them and 3 to Watch
- Wondering what penny stocks are? Here's a quick guide and three to watch The post What Are Penny Stocks, How to Trade Them and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/25/2021
|
Hot Penny Stocks to Buy As 2021 Ends? 3 to Take a Look at Now
- Check these three penny stocks out as 2021 comes to an end The post Hot Penny Stocks to Buy As 2021 Ends? 3 to Take a Look at Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/23/2021
|
Best Industries to Find Penny Stocks to Buy in 2022
- Wondering where to find penny stocks to buy in 2022? Check these three industries out The post Best Industries to Find Penny Stocks to Buy in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/23/2021
|
Trending Penny Stocks to Buy Today? 3 For Your Watchlist
- Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?
- 12/21/2021
|
5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again
- Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.
- 12/20/2021
|
Best Penny Stocks To Buy Now? 3 To Watch Before Next Week
- 3 penny stocks investors decided to buy before next week. Are they on your list right now?
- 12/17/2021
|
Trending Penny Stocks to Buy For Under $4? Check These 3 Out
- These penny stocks are trending right now, are they worth buying? The post Trending Penny Stocks to Buy For Under $4?
- 12/15/2021
|
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
- Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR). The post NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today appeared first on InvestorPlace.
- 12/13/2021
|
Biotech Penny Stocks To Buy After BLU Stock Explodes? 3 To Watch
- 3 biotech penny stocks to watch after Bellus Health (BLU) skyrockets. The post Biotech Penny Stocks To Buy After BLU Stock Explodes?
- 12/13/2021
|
Petros Pharmaceuticals Stock (PTPI): Why The Price Increased Today
- The shares of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 30% pre-market today. This is why it happened.
- 12/13/2021
|
Best Penny Stocks to Buy This Coming Week? 3 to Watch
- Here are three penny stocks to watch right now The post Best Penny Stocks to Buy This Coming Week? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/10/2021
|
4 Penny Stocks To Buy For Under $5 Before 2022
- You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/10/2021
|
Best Penny Stocks To Buy Now? 10 Short Squeeze Stocks To Watch
- Looking for potential short squeeze penny stocks? Start by looking at short interest The post Best Penny Stocks To Buy Now?
- 12/09/2021
|
3 Penny Stocks to Watch This Coming Week
- Which penny stocks are you watching this week? The post 3 Penny Stocks to Watch This Coming Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/05/2021
|
Are These Penny Stocks Worth Buying Right Now Or Not?
- Here are three penny stocks to add to your watchlist right now The post Are These Penny Stocks Worth Buying Right Now Or Not? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/03/2021
|
How to Make Money With Penny Stocks And the Omicron Variant
- Trading penny stocks right now? Consider these three tips and tricks The post How to Make Money With Penny Stocks And the Omicron Variant appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/03/2021
|
Penny Stocks To Buy For A Short Squeeze? 5 To Watch Now
- Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy For A Short Squeeze?
- 12/03/2021
|
Penny Stocks To Buy This Week: 4 To Watch Right Now
- Are these on your list of penny stocks to buy this week? The post Penny Stocks To Buy This Week: 4 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/02/2021
|
Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged
- The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by 91.39% in the most trading session. This is why it happened.
- 11/30/2021
|
What's Going On With Petros Pharmaceuticals Stock Today?
- Petros Pharmaceuticals Inc (NASDAQ: PTPI) is soaring on abnormally high volume Monday despite no apparent news catalyst. Petros Pharmaceuticals' average session volume is about 6.4 million over a 100-day period.
- 11/29/2021
|
PTPI Stock: The Short-Squeeze Buzz That Has Petros Pharmaceuticals Rocketing Today
- Petros Pharmaceuticals (PTPI) stock is taking off in pre-market trading on Monday as short-squeeze talk on social media pushes shares higher. The post PTPI Stock: The Short-Squeeze Buzz That Has Petros Pharmaceuticals Rocketing Today appeared first on InvestorPlace.
- 11/29/2021
|
Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged Today
- The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 90% pre-market today. This is why it happened.
- 11/29/2021
|
Hot Penny Stocks to Add to Your Watchlist in December
- If you're making a penny stocks watchlist for December, check these three out The post Hot Penny Stocks to Add to Your Watchlist in December appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/28/2021
|
PTPI Stock: 11 Things to Know About Penny Stock Petros Pharmaceuticals as Shares Rocket 100%+
- Petros Pharmaceuticals (PTPI) stock is surging higher on Tuesday following a filing with the U.S. Securities and Exchange Commission (SEC). The post PTPI Stock: 11 Things to Know About Penny Stock Petros Pharmaceuticals as Shares Rocket 100%+ appeared first on InvestorPlace.
- 11/23/2021
|
Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged Today
- The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 190% pre-market today. This is why it happened.
- 11/23/2021
|
Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference
- NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021. Mr. Boctor will deliver his corporate presentation on Wednesday, November 17 at 1:15 PM ET.
- 11/11/2021
|
Hot Penny Stocks to Watch as AMC and GME Go to the Moon
- Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/03/2021
|
Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged Today
- The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 90% during intraday trading today. This is why it happened.
- 11/03/2021
|
Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering
- NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering with the company's largest and other existing investors for gross proceeds of approximately $5.7 million. Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform and for working capital and general corporate purposes.
- 10/19/2021
|
Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present at the H.C.
- 09/10/2021
|
Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales
- NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2021. Second Quarter Highlights: Completed pilot label comprehension study to initiate process for STENDRA prescription erectile dysfunction medication to support the process for designation as over -the-counter treatment Initiated communications with the U.S. Food and Drug Administration regarding expansions to STENDRA's package insert (label) STENDRA® net sales increased 123% during the second quarter of 2021 vs.
- 08/17/2021
|
Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit
- New Jersey and Pennsylvania--(Newsfile Corp. - August 11, 2021) - Petros Pharmaceuticals (NASDAQ: PTPI) today announced that Fady Boctor, President, Chief Commercial Officer will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 12:30 PM ET
- 08/11/2021
|
Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021
- NEW YORK, July 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021. Mr. Boctor will deliver his corporate presentation on July 14 at 3:30pm ET.
- 07/12/2021
|
Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021
- NEW YORK, June 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021. Mr. Boctor will deliver his corporate presentation on June 10 at 4:00pm ET, Track 1.
- 06/02/2021
|
Petros Pharmaceuticals (PTPI) Stock: Over 20% Increase Explanation
- The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 20% during intraday trading. This is why it happened.
- 05/17/2021
|
Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales
- NEW YORK, May 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Petros or the Company) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the first quarter ended March 31, 2021. First Quarter Highlights: 300% increase in STENDRA® net sales during the first quarter of 2021 vs.
- 05/17/2021
|
